Lucitanib; Delitinib
Lucitanib (Delitinib) is in phase II clinical trials for the treatment of refractory FGF-aberrant metastatic breast cancer, advanced or metastatic non-small cell lung cancer, small cell lung cancer and other solid tumors.
The compound was originally developed by Advenchen Laboratories, licensed to EOS Pharmaceuticals (acquired by Clovis Oncology in 2013) (except China) in 2008. In 2012, EOS Pharmaceuticals licensed to Servier (except China, Japan and US). In 2013, Servier licensed to Shanghai Institute of Mater Medica, Chinese Academy of Sciences in China.
General Information
Update Date：2016-02-19
- Drug Name：
- Lucitanib; Delitinib
- Research Code：
- AL-3810; CO-3810; E-3810; S-80881
- Trade Name：
- MOA：
- Angiogenesis inhibitor; VEGFR1/2/3 inhibitor; FGFR1/2/3 inhibitor
- Indication：
- Breast cancer; Non small cell lung cancer (NSCLC); Small cell lung cancer (SCLC); Solid tumours
- Status：
- Phase II (Active)
- Company：
- Advenchen Laboratories (Originator) , Clovis Oncology,Servier,中国科学院上海药物研究所
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-02-18
|
Molecular Weight | 443.49 | ||||||||||||
| Formula | C26H25N3O4 | |||||||||||||
| CAS No. | 1058137-23-7 (Lucitanib); | |||||||||||||
| Chemical Name | 1-Naphthalenecarboxamide, 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl]oxy]-N-methyl- | |||||||||||||
| Lucitanib （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||